Register for our free email digests:
Latest From Ocular Therapeutix Inc.
A look at recent developments tracked by the Complete Response Letters chart on the Pink Sheet's US FDA Performance Tracker.
Ocular takes another swing at resolving the manufacturing issues that resulted in a complete response letter for its Dextenza.
The latest drug development news and highlights from our US FDA Performance Tracker.
The biotech sought a three-month action date extension with new manufacturing process data submitted to FDA just one day before the complete response letter.
- Generic Drugs
- Drug Delivery
- Therapeutic Areas
- Mylan Laboratories Inc.
- Mylan Inc.
- Western Europe
- Parent & Subsidiaries
- Agila Specialties Pvt. Ltd.
- Alphapharm Pty. Ltd.
- Dow Hickam Pharmaceuticals
- Meda AB
- Merck Generics Group
- Mylan Bertek Pharmaceuticals Inc.
- Mylan Institutional
- Mylan Laboratories Ltd.
- Mylan Pharmaceuticals Inc.
- Mylan Pharmaceuticals Pvt. Ltd.
- Mylan Specialty LP
- Mylan Technologies Inc.
- Penederm Inc.
- Somerset Pharmaceuticals Inc.
- Senior Management
Heather Bresch, CEO
Ken D Parks, CFO
Anthony Mauro, Chief Commercial Officer
- Contact Info
Phone: 1707 853000
Bldg. 4, Trident Pl.
Hatfield, PA AL10 9UL
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.